VU divests drug program to Cumberland Pharma

Through a JV-type development entity, Vanderbilt University has divested to Cumberland Pharmaceutical a program original developed by BMS, which BMS gave to the JV entity, or something like that. Cumberland notes there's no approved treatment yet for Hepatorenal Syndrome, at which the program is aimed. The release is here.